



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



Ain Shams University
Faculty of Pharmacy
Pharmaceutics & Industrial Pharmacy Department

Nanocarriers as a tool for the dermal delivery of an antifungal agent

A Thesis Submitted By

Aya Hussein Sayed Metwally

Bachelor of Pharmaceutical Sciences, Faculty of Pharmacy, Ain Shams University
Demonstrator at dept. of Pharmaceutics & Pharmaceutical Technology,
Faculty of Pharmaceutical Sciences & Pharmaceutical Industries,
Future University in Egypt

For Partial Fulfillment of Master Degree in Pharmaceutical
Sciences
(Pharmaceutics)

Under the supervision of

*Prof. Dr. Omaima A.
Sammour*

Professor of Pharmaceutics and
Industrial Pharmacy-Faculty of
Pharmacy- Ain Shams University

*Prof. Dr. Mona Ibrahim
Abdeltawab Ellassal*

Professor of Pharmaceutics and
Industrial Pharmacy- Faculty of
Pharmacy- Future university

Dr. Mona Mohamed Ahmed Abdel-Mottaleb

Associate professor of Pharmaceutics and Industrial Pharmacy-Faculty of
Pharmacy- Ain Shams University

2021

Dedicated to

My great Lovely parents

My Great Husband

My Lovely Daughter

Razan

Acknowledgment

First and foremost thanks to **God** the Most Gracious, the Most Merciful for helping me to complete this work.

To my dear supervisors, these written words are a small token of appreciation for all of the hard work that you did to keep things perspective.

No words would ever express my sincerest appreciation and gratitude to **Prof. Dr. Omaima Sammour**, Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain shams University, for her scientific adoption for me, valuable guidance, continuous supervision and great support.

I would like to express my deep appreciation and gratefulness to my supervisor; **Dr. Mona Abdel mottaleb**, Associate Professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, to whom I owe so much for her careful supervision, everlasting patience, endless giving and the valuable time she scarified throughout the process of organization, revising and proofreading that made this work possible.

I am grateful to **Dr. Mona El-Assal**, Professor of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University, for her fruitful and instructive supervision, continuous advice, valuable guidance, afforded help and support during the course of the thesis.

Special Thanks to **Dr. Shady**, lecturer of Dermatology, STDs & Andrology, Faculty of Medicine, Al-Minya University, for his kind help in the clinical study part in this thesis.

I am deeply thankful to Gattefosse and Cargill Pharmaceutical Companies for supplying some of the pharmaceutical ingredients used in this work.

Special Thanks to **Dr. Sara zahran**, lecturer of microbiology, Faculty of Pharmacy, Future University, for her help during my work in the microbiological testing.

I am profoundly grateful to all the staff members of the Pharmaceutics & Pharmaceutical Technology Department, Faculty of Pharmacy, Future University and my colleagues who have sincerely encouraged and helped me.

Last and but not least, this work could not have been accomplished without the support and encouragement of my precious family for their sincere encouragement to complete this work. To all of you, thank you.

Aya Hussein

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	iii
List of Abbreviations	ix
Abstract.....	xi
General Introduction	1
Scope of Work	41
Chapter 1: Preparation and Characterization of Lipid Nanocapsules Using Essential Oils with Antifungal Activity	44
Introduction.....	44
Experimental.....	50
Materials.....	50
Equipment.....	50
Methodology.....	51
1-Preparation of LNCs	51
2-Preliminary screening of different potential natural oils for the possible preparation of LNCs	52
3- Preliminary screening of different surfactants for the preparation of LNCs.....	52
4- Construction of ternary phase diagram for the preparation of LNCs	53
5- Characterization of the prepared lipid nanocapsules	54
5-1-Determination of particle size and polydispersity index (PDI)	54
5-2-Determination of zeta potential	54
5-3-Effect of storage on the physical stability of LNCs.....	54
5-4-Determination of the morphology of LNCs using transmission electron microscope (TEM)	55
5-5- Viscosity measurement of selected formulations	55
5-6- Microbiological evaluation of selected formulations	55
6-Statistical analysis.....	57
Results and Discussion.....	58
1- Preliminary screening of different natural oils for the preparation of LNCs	58
2- Preliminary screening of different surfactants for the preparation of LNCs	62
4- Construction of ternary phase diagram for the preparation of LNCs	66
5-Characterization of the prepared lipid nanocapsules	82
5-1- Determination of particle size and polydispersity index (PDI)	82
5-2-Determination of zeta potential.....	82

5-3-Effect of storage on the physical stability of LNCs	82
5-4-Microscopical imaging of LNCs using transmission electron microscope (TEM)	93
5-5- Viscosity measurement of selected formulations	95
5-6-Microbiological evaluation of selected formulations	97
Conclusions.....	100
Chapter 2: Preparation, characterization and ex-vivo evaluation of luliconazole loaded lipid nanocapsules (LNCs)	101
Introduction.....	101
Experimental.....	103
Materials.....	103
Equipment.....	103
Methodology.....	105
1-Spectrophotometric assay of Luliconazole	105
1-1-UV scanning of luliconazole in ethanol	105
1-2-Construction of calibration curve of luliconazole in ethanol.....	105
1-3-Construction of calibration curve of luliconazole in [pH 5.5 acetate buffer/ethanol (6:4)].....	105
2-Measurement of luliconazole solubility in different oils.....	106
3- Preparation of luliconazole loaded Lipid nanocapsules.....	106
4-Determination of particle size and polydispersity index (PDI).....	109
5-Determination of zeta potential.....	109
6- Effect of storage on the physical stability of luliconazole loaded LNCs	109
7- Viscosity measurement.....	110
8- Evaluation of the <i>in-vitro</i> luliconazole release from the selected LNCs	110
9-Ex-vivo skin permeation study of Luliconazole from the selected LNCs	111
10-Ex-vivo skin deposition study of Luliconazole from the selected LNCs	112
11-Determination of the morphology of luliconazole loaded LNCs using transmission electron microscope (TEM).....	113
12-Microbiological evaluation of selected luliconazole loaded LNCs formulae.....	113
13- Statistical analysis.....	114
Results and Discussion.....	115
1-Spectrophotometric assay of Luliconazole	115
1-1-UV scanning of Luliconazole in ethanol	115
1-2-Construction of calibration curve of Luliconazole in ethanol	116
1-3-Construction of calibration curve of Luliconazole in [pH 5.5 acetate buffer/ethanol (6:4)].....	117
2- Measurement of Luliconazole solubility in different oils.....	119
3-Determination of particle size and polydispersity index (PDI)	120

4-Determination of zeta potential.....	121
5- Effect of storage on the physical stability of luliconazole loaded LNCs	122
6- Viscosity measurements	126
7- <i>In-vitro</i> luliconazole release from the selected LNCs	136
8- <i>Ex-vivo</i> deposition/permeation of luliconazole loaded LNCs	141
9-Microscopical imaging of luliconazole loaded LNCs using transmission electron microscope (TEM).....	147
10-Microbiological evaluation of selected LNCs formulae	149
Conclusions.....	151
Chapter 3: In-vivo and clinical studies of selected luliconazole loaded lipid nanocapsules (LNCs)	152
Introduction.....	152
Experimental.....	157
Materials.....	157
Formulae tested	157
Animals.....	157
Pathogens	158
Methodology.....	158
1. <i>In-vivo</i> therapeutic efficiency evaluation	158
1-1. Induction of cutaneous candidasis infection.....	159
1-2. Treatment of infection.....	159
1.3. Assessment of antifungal efficacy	160
2. Clinical proof of the efficacy of LNCs in treatment of skin fungal infections (Tinea pedis)	161
2-1. Design of the clinical study	161
2-2. Clinical response.....	163
3. Statistical analysis.....	165
Results and Discussion.....	166
1. <i>In-vivo</i> therapeutic efficiency evaluation	166
2. Clinical proof of efficacy of LNCs in treatment of skin fungal infections (Tinea pedis)	181
Conclusions.....	189
Recommendations and Future perspective.....	190
Summary	191
References	201
Appendix.....	—
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Initial experimental domains for the formulation of lipid nanocapsules	54
Table (2):	Preliminary screening of different natural oils for the preparation of LNCs.....	59
Table (3):	Preliminary screening of different surfactants for the preparation of LNCs:	65
Table (4):	Composition, particle size analysis data and zeta potential of different Orange oil formulations.	69
Table (5):	Composition, particle size analysis data and zeta potential of different eucalyptus oil formulations.....	75
Table (6):	Effect of six months storage at 4±1°C on the particle size, PDI and zeta potential of orange oil LNCs.....	84
Table (7):	Effect of six months storage at 4±1°C on the particle size, PDI and zeta potential of eucalyptus oil LNCs.....	91
Table (8):	Single point viscosity of O36 and E35 LNCs.	96
Table (9):	Inhibition zones produced by <i>in-vitro</i> antimycotic activity of different LNCs formulae using <i>C. albicans</i> as the test organism.	98
Table (10):	Composition of different Orange oil luliconazole loaded LNCs formulations.	108
Table (11):	Composition of different Eucalyptus oil luliconazole loaded LNCs formulations.	108
Table (12):	UV absorbance of luliconazole solution in ethanol at λ_{max} of 296.6nm.	117
Table (13):	UV absorbance of luliconazole solution in [pH 5.5 acetate buffer/ethanol (6:4)] at λ_{max} of 296.6nm.....	118
Table (14):	Solubility of luliconazole in various oils	119
Table (15):	Particle size, PDI and Zeta potential of Orange oil luliconazole loaded LNCs	124
Table (16):	Particle size, PDI and Zeta potential of Eucalyptus oil luliconazole loaded LNCs	125

List of Tables Cont...

Table No.	Title	Page No.
Table (17):	Formulation consistency, viscosity values and cumulative percent released of luliconazole from selected orange oil based LNCs formulae.....	139
Table (18):	Formulation consistency, viscosity values and cumulative percent released of luliconazole from selected eucalyptus oil based LNCs formulae	139
Table (19):	Amounts of luliconazole deposited of LNCs formulae compared to luliconazole solution in orange oil and luliconazole solution in eucalyptus oil.....	145
Table (20):	Flux rate of luliconazole from LNCs formulae compared to luliconazole solution in orange oil and luliconazole solution in eucalyptus oil.....	146
Table (21):	Therapeutic efficacy of different treatments of cutaneous candidiasis assessed by the number of culture positive skin blocks after 7 days of treatment.....	167
Table (22):	Demographic data of patients receiving formulae E35l, E35, O25l and M25l	185
Table (23):	Assessment of group A patients receiving formula E35l for 10 days.	185
Table (24):	Assessment of group B patients receiving formula E35 for 10 days.	186
Table (25):	Assessment of group C patients receiving formula O25l for 10 days.....	186
Table (26):	Assessment of group D patients receiving formula M25l for 10 days.	187

List of Figures

Fig. No.	Title	Page No.
Figure (I):	Diagrammatic cross- section of human skin showing different skin layers and appendages	6
Figure (II):	Sketch of the three penetration pathways	10
Figure (III):	Representation of vesicular liposomal structure.....	17
Figure (IV):	Representation of a niosome structure.....	18
Figure (V):	Representation of transfersome structure	20
Figure (VI):	Representation of ethosomes structure	22
Figure (VII):	Flow chart showing mechanism of action of Ethosomes.....	22
Figure (VIII):	A cubosome exhibiting its cavernous internal and cubic structure and its membrane composition.....	25
Figure (IX):	Different types of polymer-based nanoparticles.....	28
Figure (X):	Structure of SLNs	31
Figure (XI):	SLNs entrapping an antifungal drug.....	31
Figure (XII):	Representation of hybrid structure of LNCs.....	35
Figure (XIII):	Chemical structure of luliconazole.	38
Figure (XIV):	Diagrammatic representation of the preparation process of LNCs	46
Figure (XV):	Essential oil action against fungi	48
Figure (XVI):	Innate immunity against C. albicans skin infection	156